Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Atanase Craciun

Neurology Cleveland, OH Medical Doctor

NPI 1487666350 CMS profile 1259138

9500 Euclid Ave, Cleveland, OH 44195

Open in the dashboard

General payments

$2,985

103 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Atanase Craciun of Cleveland, OH is reported in the CMS Open Payments database as having received $2,985 across 103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $288 2
2024 General $457 19
2023 General $769 23
2022 General $366 20
2021 General $539 23
2020 General $53 3
2019 General $513 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Atanase Craciun
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Atanase Craciun were reported at $288. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Atanase Craciun Neurology median Middle half National median
2019 $513 $474 $118–$2,177 $163
2020 $53 $367 $82–$2,309 $114
2021 $539 $438 $104–$2,547 $132
2022 $366 $442 $103–$2,388 $149
2023 $769 $464 $119–$2,312 $160
2024 $457 $468 $119–$2,323 $164
2025 $288 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $689 12 payments
  2. Harmony Biosciences LLC $529 27 payments
  3. Genzyme Corporation $249 13 payments
  4. Alexion Pharmaceuticals, Inc. $238 3 payments
  5. Novartis Pharmaceuticals Corporation $194 9 payments
  6. Genentech USA, Inc. $148 2 payments
  7. Celgene Corporation $147 10 payments
  8. Eisai Inc. $146 2 payments
  9. Inspire Medical Systems, Inc. $138 1 payment
  10. Jazz Pharmaceuticals Inc. $100 1 payment
  11. Other $407 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,959 90 payments
  2. Consulting Fee $600 4 payments
  3. Education $426 9 payments
Products named General payments · program years 2019–2025
  1. TYSABRI $673 10 payments
  2. WAKIX Sleep Medicine $301 12 payments
  3. WAKIX Narcoplepsy $228 15 payments
  4. AUBAGIO $197 10 payments
  5. ZEPOSIA $147 10 payments
  6. INSPIRE $138 1 payment
  7. KESIMPTA $135 6 payments
  8. Soliris $125 1 payment
  9. ULTOMIRIS $113 2 payments
  10. XYWAV $100 1 payment
  11. Other $512 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 109 drugs

Part D claims

7,207

Median for Neurology: 833

Drug cost

$1,323,443

Median for Neurology: $202,670

Branded share of claims

24.6%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Copaxone Glatiramer Acetate Brand 37 $240,993
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 12 $170,344
Teriflunomide Generic 39 $129,055
Zeposia Ozanimod Hydrochloride Brand 13 $118,550
Glatopa Glatiramer Acetate Brand 32 $117,447
Nuplazid Pimavanserin Tartrate Brand 20 $96,779
Wakix Pitolisant Hcl Brand 12 $96,563
Briviact Brivaracetam Brand 22 $42,283
Eliquis Apixaban Brand 36 $28,734
Dalfampridine Er Dalfampridine Brand 72 $24,468

The 10 drugs with the highest cost, of 109 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$68,046

Medicare's payments for the services billed

Medicare patients

561

Average age 74

Services billed

1,019

321 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Depression 31%
Diabetes 29%
Chronic kidney disease 29%
Ischemic heart disease 24%
Heart failure 20%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAKIX
  • Harmony Biosciences LLC $228
$228 12 —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $113
$113 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $100
$100 — —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record